JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment

  • 0Shandong University of Traditional Chinese Medicine, Jinan, 250013, Shandong, China.
Discover Oncology +

|

February 22, 2025

|

February 22, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies a seven-gene signature of efferocytosis-related long noncoding RNAs (ERLncRNAs) for predicting outcomes and guiding immunotherapy in clear cell renal cell carcinoma (ccRCC). The signature aids in assessing prognosis and treatment response in ccRCC patients.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • The role of efferocytosis-related long noncoding RNAs (ERLncRNAs) in clear cell renal cell carcinoma (ccRCC) remains underexplored.
  • Understanding these ERLncRNAs is crucial for developing novel prognostic and therapeutic strategies for ccRCC.

Purpose Of The Study

  • To identify and validate a prognostic signature of ERLncRNAs in ccRCC.
  • To characterize the immune landscape and predict immunotherapeutic response based on the ERLncRNA signature.

Main Methods

  • Utilized The Cancer Genome Atlas (TCGA) data for ccRCC samples.
  • Employed bioinformatics analyses including Pearson correlation, LASSO, and Cox regression for signature development.
  • Assessed immune cell infiltration, tumor mutational burden (TMB), tumor microenvironment (TME), and drug sensitivity.

Main Results

  • A novel seven-ERLncRNA signature (LINC01615, RUNX3-AS1, FOXD2-AS1, AC002070.1, LINC02747, LINC00944, AC092296.1) was identified.
  • The signature demonstrated strong prognostic prediction capabilities, validated by Kaplan-Meier, ROC curves, nomogram, and C-index.
  • Significant differences in immune landscape and TME characteristics were associated with the signature.

Conclusions

  • The developed seven-ERLncRNA signature holds significant potential for prognostic prediction in ccRCC.
  • This signature may serve as a valuable tool for assessing immunotherapeutic response in ccRCC patients.

Keywords:

Related Concept Videos

lncRNA - Long Non-coding RNAs 02:39

8.5K

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

The Tumor Microenvironment 02:17

6.5K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Mitogens and the Cell Cycle 02:38

6.4K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...